| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.041 | 0.6 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.039 | 0.6 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.6 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.6 |